Merck & Company -Evaluating a Drug Licensing Opportunity(영문)

  • 등록일 / 수정일
  • 페이지 / 형식
  • 자료평가
  • 구매가격
  • 2009.02.13 / 2019.12.24
  • 7페이지 / fileicon doc (MS워드 2003이하)
  • 평가한 분이 없습니다. (구매금액의 3%지급)
  • 1,400원
다운로드장바구니
Naver Naver로그인 Kakao Kakao로그인
최대 20페이지까지 미리보기 서비스를 제공합니다.
자료평가하면 구매금액의 3%지급!
이전큰이미지 다음큰이미지
목차
INTRODUCTION
Merck & Company : Evaluating the Licensing Opportunity
Brief introduction of Merck and its agenda regarding Davanrik project
1. Expectaion of costs and chances of success for each phase
2. Cost of launches and Potential profits
3. Decision Tree & Calculation
CONCLUSION
본문내용
Merck & Company : Evaluating the Licensing Opportunity

Various recently-born biotech companies sell their technologies in either finished or early stage to bigger companies in need of financing capital to preceed business, while those bigger companies acquire technologies to scout for promising profitable business. This sort of process needs numbers of decision makings and agreements from both parties on the valuation methods is crucial here. The valuation method being used has to hold objective validity and generality.
For the managers to make accurate forecast of future profitability in managing companies, quantified decision making process is needed. Here we are dealing about whether Merck should give financial support to the R&D project of Davanrik offered by LAB, and about the process of valuation and the final decision. First we are to make brief of LAB’s business proposal and practice detailed valuation functions to decide if the proposal is profitable or not. And finally we will make a decision based on the valuation process in perspective of Rich Kender, Vice President of Financial Evaluation & Analysis of Merck.

Brief introduction of Merck and its agenda regarding Davanrik project
As a world-class pharmaceutical company concentrated on R&Ds, Merck is performing various researches and developments upon medical supplies for human and animals. Merck is providing Pharmaceutical Benefit Management (i.e. PBM) through a company called Merck-Medco Managed Care. Apparently it is a giant pharmaceutical company with more than 15 blockbuster medical supplies, revenue of $3270 million and net profit of $590 million, ever since 1995. One constraint of Merck is that most of its profit is over-concentrated on the major top 4 items, and in order to diversification of profits Merck is facing a pressure to launch a new business item or take another complementary strategy through biotech and internal R&D.

LAB Pharmaceuticals has already finished developing Davanrik, an antidepressant. Even though it carries substantial medical/economical feasibility for being effective on both hypochondria and obesity, LAB cannot afford the capital to proceed clinical demonstrations ahead the actual sale to acquire licensing. This is the reason why LAB offered Merck of technical affiliation.

At the following step, we are to evaluate the profitability of Davanrik based on the expected length of time and expense, chances of success that LAB has suggested.
자료평가
    아직 평가한 내용이 없습니다.
회원 추천자료
  • [영어]공무원 영어시험
  • a team of archaeologists at the university, the director of the project ② emphasized that the tablets would provide important ③ insights ④ into the routine lives of early Hittites.-2000. 5. 행자부 기출문제 -※ 다음 글을 영어로 옮길 때 밑줄 친 부분에 각각 들어갈 적합한 단어는?“영어회화에 숙달하려면 외국인과 영어로 얘기할 수 있는 기회를 활용하는 것이 중요하다.”⇒ you to master English conversation. it is important to use of opportunities of talking with foreigners English.① Of - make - in ② For -

  • [전략경영] Coca Cola(코카콜라) 사례 분석(영문)
  • opportunity that we have seen being put to use before is the ability for Coca Cola to buy out their competition. This opportunity rarely presents itself in the world of business. However, with Coca Cola’s power and success, such a task is not impossible. Brand recognition is the significant factor affecting Cokes competitive position. Coca Cola is known well throughout 90% of the world population today. Now Coca Cola wants to get there brand name known even better and possibly get closer and closer to 100%. It is an opportunity that most companies will ever dream of, and would be a supreme

  • 일본의 화장품시장 분석 및 진출 방안 연구(영문)
  • Companies need licenses and people need to pass tests for doing all kinds of things. Traditionally 80 percent of policies were shaped by bureaucrats and 20 percent by elected country leaders. There are over one million civil servants in the Japanese government and the economic ministries. The national bureaucracy includes 332,999 general administration staff. Many bureaucrats are graduates of Japans most prestigious universities and often carry themselves with a swagger usually associated with important politicians and executives. In 1996, 45,000 of Japans brightest young people applied for

  • [조직개발] 한미약품 co. Bio-tech R&D Unit
  • a same starting line and there was a possibility Hanmi capture the opportunity to succeed through a original product in the future. So it was reasonable choice to enter the bio-tech market considering their vision and market situation.But considering their capability to manage a original product R&D unit, there are a lot of difficulties they have to overcome. First of all they have a matter of size. Compared with Korean companies they are big player but compared with global companies they are small player so they get some trouble in terms of investment.They also have some trouble due to la

  • CJ푸드빌 SWOT 분석 및 경영전략(영문)
  • a decrease in sales revenue. Also, the industry is experiencing the difficulties with the increase of price in imported input cost and distribution cost resulted from the increased oil price.Franchise bakery has a good prospect in the future as well as the current status. The bakeries would promote its brand and the products with the large budget and the brand power. There would be a gradual progress in setting up the diversified marketing strategies such as cooperation with companies of other field like telecom, credit card. Also, they are likely to use the way to improve the sales revenue

사업자등록번호 220-06-55095 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.02-539-9392
개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1806호 이메일 help@reportshop.co.kr
copyright (c) 2003 reoprtshop. steel All reserved.